vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and POTLATCHDELTIC CORP (PCH). Click either name above to swap in a different company.
POTLATCHDELTIC CORP is the larger business by last-quarter revenue ($314.2M vs $183.1M, roughly 1.7× Amphastar Pharmaceuticals, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs 8.2%, a 5.1% gap on every dollar of revenue. On growth, POTLATCHDELTIC CORP posted the faster year-over-year revenue change (23.1% vs -1.8%). POTLATCHDELTIC CORP produced more free cash flow last quarter ($50.1M vs $24.6M). Over the past eight quarters, POTLATCHDELTIC CORP's revenue compounded faster (11.1% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
POTLATCHDELTIC CORPPCHEarnings & Financial Report
PotlatchDeltic Corporation is an American diversified forest products company based in Spokane, Washington.
AMPH vs PCH — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $314.2M |
| Net Profit | $24.4M | $25.9M |
| Gross Margin | 46.8% | 18.2% |
| Operating Margin | 19.4% | 11.2% |
| Net Margin | 13.3% | 8.2% |
| Revenue YoY | -1.8% | 23.1% |
| Net Profit YoY | -35.7% | 682.5% |
| EPS (diluted) | $0.51 | $0.33 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | — | ||
| Q3 25 | $191.8M | $314.2M | ||
| Q2 25 | $174.4M | $275.0M | ||
| Q1 25 | $170.5M | $268.3M | ||
| Q4 24 | $186.5M | $258.1M | ||
| Q3 24 | $191.2M | $255.1M | ||
| Q2 24 | $182.4M | $320.7M | ||
| Q1 24 | $171.8M | $228.1M |
| Q4 25 | $24.4M | — | ||
| Q3 25 | $17.4M | $25.9M | ||
| Q2 25 | $31.0M | $7.4M | ||
| Q1 25 | $25.3M | $25.8M | ||
| Q4 24 | $38.0M | $5.2M | ||
| Q3 24 | $40.4M | $3.3M | ||
| Q2 24 | $37.9M | $13.7M | ||
| Q1 24 | $43.2M | $-305.0K |
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | 18.2% | ||
| Q2 25 | 49.6% | 13.0% | ||
| Q1 25 | 50.0% | 17.8% | ||
| Q4 24 | 46.5% | 13.4% | ||
| Q3 24 | 53.3% | 10.8% | ||
| Q2 24 | 52.2% | 11.9% | ||
| Q1 24 | 52.4% | 7.0% |
| Q4 25 | 19.4% | — | ||
| Q3 25 | 13.2% | 11.2% | ||
| Q2 25 | 24.2% | 5.0% | ||
| Q1 25 | 21.9% | 10.3% | ||
| Q4 24 | 24.2% | 5.2% | ||
| Q3 24 | 29.8% | 2.8% | ||
| Q2 24 | 30.3% | 5.4% | ||
| Q1 24 | 27.9% | -2.1% |
| Q4 25 | 13.3% | — | ||
| Q3 25 | 9.0% | 8.2% | ||
| Q2 25 | 17.8% | 2.7% | ||
| Q1 25 | 14.8% | 9.6% | ||
| Q4 24 | 20.4% | 2.0% | ||
| Q3 24 | 21.1% | 1.3% | ||
| Q2 24 | 20.8% | 4.3% | ||
| Q1 24 | 25.1% | -0.1% |
| Q4 25 | $0.51 | — | ||
| Q3 25 | $0.37 | $0.33 | ||
| Q2 25 | $0.64 | $0.09 | ||
| Q1 25 | $0.51 | $0.33 | ||
| Q4 24 | $0.74 | $0.07 | ||
| Q3 24 | $0.78 | $0.04 | ||
| Q2 24 | $0.73 | $0.17 | ||
| Q1 24 | $0.81 | $0.00 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $88.8M |
| Total DebtLower is stronger | $608.7M | — |
| Stockholders' EquityBook value | $788.8M | $1.9B |
| Total Assets | $1.6B | $3.2B |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | — | ||
| Q3 25 | $276.2M | $88.8M | ||
| Q2 25 | $231.8M | $95.3M | ||
| Q1 25 | $236.9M | $147.5M | ||
| Q4 24 | $221.6M | $151.6M | ||
| Q3 24 | $250.5M | $161.1M | ||
| Q2 24 | $217.8M | $199.7M | ||
| Q1 24 | $289.6M | $180.2M |
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | $1.0B | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | — | ||
| Q3 25 | $776.7M | $1.9B | ||
| Q2 25 | $757.5M | $1.9B | ||
| Q1 25 | $751.3M | $2.0B | ||
| Q4 24 | $732.3M | $2.0B | ||
| Q3 24 | $727.7M | $2.1B | ||
| Q2 24 | $713.3M | $2.1B | ||
| Q1 24 | $672.4M | $2.2B |
| Q4 25 | $1.6B | — | ||
| Q3 25 | $1.7B | $3.2B | ||
| Q2 25 | $1.6B | $3.2B | ||
| Q1 25 | $1.6B | $3.3B | ||
| Q4 24 | $1.6B | $3.3B | ||
| Q3 24 | $1.5B | $3.3B | ||
| Q2 24 | $1.5B | $3.4B | ||
| Q1 24 | $1.6B | $3.4B |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | 0.51× | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $65.7M |
| Free Cash FlowOCF − Capex | $24.6M | $50.1M |
| FCF MarginFCF / Revenue | 13.4% | 15.9% |
| Capex IntensityCapex / Revenue | 4.5% | 4.9% |
| Cash ConversionOCF / Net Profit | 1.35× | 2.54× |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $132.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | — | ||
| Q3 25 | $52.6M | $65.7M | ||
| Q2 25 | $35.6M | $41.0M | ||
| Q1 25 | $35.1M | $49.1M | ||
| Q4 24 | $29.0M | $45.4M | ||
| Q3 24 | $60.0M | $26.5M | ||
| Q2 24 | $69.1M | $100.6M | ||
| Q1 24 | $55.3M | $16.0M |
| Q4 25 | $24.6M | — | ||
| Q3 25 | $47.2M | $50.1M | ||
| Q2 25 | $25.0M | $30.6M | ||
| Q1 25 | $24.4M | $26.3M | ||
| Q4 24 | $16.6M | $25.4M | ||
| Q3 24 | $46.2M | $-8.2M | ||
| Q2 24 | $63.1M | $72.4M | ||
| Q1 24 | $46.5M | $2.0M |
| Q4 25 | 13.4% | — | ||
| Q3 25 | 24.6% | 15.9% | ||
| Q2 25 | 14.3% | 11.1% | ||
| Q1 25 | 14.3% | 9.8% | ||
| Q4 24 | 8.9% | 9.9% | ||
| Q3 24 | 24.1% | -3.2% | ||
| Q2 24 | 34.6% | 22.6% | ||
| Q1 24 | 27.1% | 0.9% |
| Q4 25 | 4.5% | — | ||
| Q3 25 | 2.8% | 4.9% | ||
| Q2 25 | 6.1% | 3.8% | ||
| Q1 25 | 6.3% | 8.5% | ||
| Q4 24 | 6.7% | 7.7% | ||
| Q3 24 | 7.2% | 13.6% | ||
| Q2 24 | 3.3% | 8.8% | ||
| Q1 24 | 5.1% | 6.1% |
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | 2.54× | ||
| Q2 25 | 1.15× | 5.58× | ||
| Q1 25 | 1.39× | 1.90× | ||
| Q4 24 | 0.76× | 8.74× | ||
| Q3 24 | 1.48× | 7.99× | ||
| Q2 24 | 1.82× | 7.35× | ||
| Q1 24 | 1.28× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
PCH
| Lumber | $131.8M | 42% |
| Timberlands | $52.5M | 17% |
| Rural Real Estate | $51.3M | 16% |
| Residuals And Panels | $34.0M | 11% |
| Pulpwood | $16.7M | 5% |
| Development Real Estate | $14.6M | 5% |
| Other | $8.1M | 3% |
| Other Products | $5.2M | 2% |
